SCHEDULE: FMR LLC Discloses 5.1% Stake in Teva Pharma
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson report a 5.1% beneficial ownership of Teva Pharmaceutical Industries Ltd. common stock.
Summary
- FMR LLC and Abigail P. Johnson, as reporting persons, collectively hold beneficial ownership of 58,135,616.48 shares of Teva Pharmaceutical Industries Ltd. common stock.
- This aggregate amount represents 5.1% of the class of Teva Pharmaceutical Industries Ltd. common stock.
- FMR LLC holds sole voting power over 54,563,822.43 shares.
- Both FMR LLC and Abigail P. Johnson hold sole dispositive power over 58,135,616.48 shares.
- The filing is an Amendment No. 2 to Schedule 13G, indicating a previous filing for this ownership.
- The beneficial ownership is reported as of June 30, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A Schedule 13G is a passive ownership disclosure, not a performance report. The disclosure of a significant 5.1% stake by a prominent institutional investor like FMR LLC can be viewed as a positive signal of confidence in the company, though it does not imply active management or strategic influence.
Positives
- The disclosure of a significant 5.1% stake by a major institutional investor like FMR LLC indicates continued institutional interest in Teva Pharmaceutical Industries Ltd.
Negatives
- This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information regarding the operational or financial performance of Teva Pharmaceutical Industries Ltd. that would typically be categorized as negatives.
Risks
- This Schedule 13G filing is a disclosure of beneficial ownership and does not detail specific operational or financial risks pertaining to Teva Pharmaceutical Industries Ltd. The filing indicates a passive investment, not an intent to influence control.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the future outlook of Teva Pharmaceutical Industries Ltd.
Industry Context
This filing reflects a significant passive investment by a major asset manager in a pharmaceutical company. Such disclosures are common in the industry as large funds manage diverse portfolios, but this specific filing does not provide broader industry trend analysis or competitive insights.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by FMR LLC may be viewed positively by other shareholders, potentially signaling confidence in the company's long-term prospects.
- Management: While the filing indicates a passive investment, a large institutional shareholder can indirectly influence management decisions through voting on proposals, though no such intent is stated.
Key Dates
| Date | Description |
|---|---|
| 05/23/2023 | Effective date of Power of Attorney for Richard Bourgelas to sign on behalf of FMR LLC and Abigail P. Johnson. |
| 08/08/2023 | Date of previous Schedule 13G filing by FMR LLC, where the Power of Attorney was incorporated by reference. |
| 06/30/2025 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 08/05/2025 | Signature date of the Schedule 13G filing. |
Keywords
Teva Pharmaceutical Industries Ltd., FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.